Social Media Ideas for Incyte

Specialised Therapeutics expands Incyte partnership to Australia

Incyte: Digesting The ESMO Updates In Pancreatic, Colorectal, And Ovarian Cancer

<![CDATA[Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Ente...

<![CDATA[Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz ]]>

<![CDATA[InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly]]>

Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet

TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance

Eli Lilly-partnered TRexBio will apply the IPO proceeds toward clinical development of molecules designed to activate regulatory T cells to mediate immune responses and inflammatio...

<![CDATA[Cellectis Transforming Into In Vivo Gene Editing Company]]>

Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture...

FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant’s Biz Strategy

Roivant Sciences subsidiary Priovant Therapeutics received FDA approval for Lisraya as a treatment for the rare inflammatory disorder dermatomyositis. Licensed from Pfizer, this on...

<![CDATA[Merck Licenses Preclinical KRAS G12D Inhibitor from SciBrunch]]>

Merck KGaA bets on RNAi with $1.3B Silence buyout

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.

Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication f...

INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication...

<![CDATA[Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Th...

Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer

The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera. Silence’s RNA therapy offers a different approach and...

Fed. Circ. Upholds Block On MSN Cancer Drug In Exelixis Win

The Federal Circuit on Monday rejected MSN Laboratories' argument that three Exelixis patents on the blockbuster cancer drug Cabometyx are invalid, while dismissing as moot an appe...

<![CDATA[Roundup: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy, Enodia Therapeut...

Eli Lilly’s pipeline in 2026: how the incretin boom is funding what comes next 

Take a look at the Eli Lilly pipeline in 2026 as the incretin franchise grows and fuels the rest of the company's pipeline. The post Eli Lilly’s pipeline in 2026: how the incretin...

<![CDATA[METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies]]&gt...

<![CDATA[Roundup: Nanexa, Earendil Labs, and Atavistik Bio Enter Platform Deals with Novo Nordisk, Genentech, and Roc...

Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment

Intracellular?

Intracellular? Anonymous (not verified) Mon, 09/07/2026 - 15:50 field_thread_url https://cafepharma.com/boards/threads/intracellular.716225/...

Roivant, continuing ascent, claims another victory for rare disease drug

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also be a “best-in-disease” medicine for an inflammatory eye...

Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact

Eli Lilly’s partnership with InnoCare Pharma follows deals struck this year with other China-based companies. While indications for the new alliance remain undisclosed, InnoCare sp...